Latest From Daniel Chancellor
Investors at the Advanced Therapies Europe conference in London struck a bullish note on the state of the market and offered up advice for cell and gene developers from fundraising, platform development to manufacturing.
This article reveals the top 10 pharmaceutical products by revenues in 2022 and discusses the major themes affecting the highest-grossing drugs and the companies behind their continued development.
Speaking at BIO-Europe Spring, three leaders of platform life sciences companies offer advice on their scalable and lower risk business models that support innovation within partner biopharma companies.
As the world begins its transition into a post-pandemic existence, it becomes possible to look back on the past two years and begin to quantify the effects COVID-19 has brought. For the biopharmaceutical industry, clinical trials have been at the forefront.
Best practices to help sponsors design patient-centric studies, build trial awareness among important physician and health care professional groups, leverage advocacy groups to speed up patient recruitment, and ultimately gain a competitive edge in rare disease trial strategies.
Gene editing is positioning itself as the latest evolution of genetic therapies and is due for an inflection point in 2022 as a number of milestones will be reached.